BioAge Labs could more than double amid the release of more data on its anti-inflammation and weight loss drugs over the next year, according to BTIG. The investment firm initiated coverage of the biopharmaceutical name with a buy rating. It also set a $40 price target on shares, implying 120% upside from Tuesday’s close. “BioAge represents an impressive combination of rigorous translational science, a proprietary, hard to duplicate, human-aging, dataset, and a focus on aging and chronic inflammation: key frontiers of drug development,” analyst Thomas Shrader said Wednesday in a note to clients. The analyst pointed to BGE-102, an oral therapy targeting age-related inflammation, as the firm’s main value driver. An update on its efficacy in clinical trials, which should come out in the second half of this year, should boost BioAge stock, he added. “Management frames the oral format as a key commercial differentiator, enabling potential prescribing at scale by primary care physicians alongside statins, analogous to lipid-lowering therapy adoption,” Shrader wrote. A newer drug called BGE-105 also promises to propel BioAge shares higher, according to BTIG. The under-development treatment has shown the “strongest synergy with GLP-1 weight loss drugs of any approach seen to date.” More data on the drug should be released in the middle of next year, which could serve as another catalyst for BioAge stock. BTIG’s call falls in line with consensus on Wall Street. Of the seven analysts covering BioAge Labs, five have a buy or strong buy on the stock, LSEG data shows. Shares have jumped 38% in the year to date, outperforming the overall market.
